BioNTech SE
BNTX
$107.34
-$0.16-0.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -84.83% | -7.31% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -84.83% | -7.31% | |||
| Cost of Revenue | -66.02% | 31.97% | |||
| Gross Profit | -89.67% | -13.90% | |||
| SG&A Expenses | -9.87% | -14.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -218.20% | -87.58% | |||
| Total Operating Expenses | -35.19% | -18.28% | |||
| Operating Income | -407.94% | 635.33% | |||
| Income Before Tax | -245.99% | 84.02% | |||
| Income Tax Expenses | -170.08% | 202.62% | |||
| Earnings from Continuing Operations | -258.18% | 27.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -258.18% | 27.01% | |||
| EBIT | -407.94% | 635.33% | |||
| EBITDA | -260.20% | 313.24% | |||
| EPS Basic | -258.15% | 27.70% | |||
| Normalized Basic EPS | -225.16% | 61.34% | |||
| EPS Diluted | -258.52% | 28.97% | |||
| Normalized Diluted EPS | -225.16% | 63.32% | |||
| Average Basic Shares Outstanding | 0.03% | -0.54% | |||
| Average Diluted Shares Outstanding | 0.03% | -1.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||